What's new in HCV genotype 2 treatment

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Genotype 2 (HCV-2) accounts for 8% of the patients with chronic hepatitis C virus in Europe. Because of the favourable response to interferon (IFN)-based treatment, this group is considered an 'easy-to-treat' genotype along with HCV-3. However, experimental and clinical data suggest possible differences between HCV-2 and -3. Recently, subtle differences in treatment efficacy have also been shown in response-guided treatment studies. In these studies, the duration of pegylated interferon (PEG-IFN) and ribavirin (RBV) treatment was tailored according to treatment response. Although SVR rates were similar between HCV-2 and HCV-3 patients after a rapid virological response (RVR), in the absence of RVR, the rates were lower in HCV-3 than in HCV-2. The triple combination treatment, including direct-acting antivirals (DAA) that will be commercialized in the coming months might increase SVR rates in this particular subgroup of patients. According to existing results, telaprevir might be beneficial in HCV-2 but not in HCV-3 patients. A nucleotide analogue polymerase inhibitor, PSI-7977 by Pharmasett has been shown to be active against both. The role of the IL28B polymorphism as a predictor of response to the current standard of care (SoC), PEG-IFN and RBV treatment is the subject of debate, but this mainly seems to be because of the small size of the samples in the studies performed so far. Existing results suggest that the genetic evaluation of IL28B may be useful in patients with HCV-2 for predicting response in patients without RVR.

Original languageEnglish
Pages (from-to)135-140
Number of pages6
JournalLiver International
Volume32
Issue numberSUPPL. 1
DOIs
Publication statusPublished - Feb 2012

Fingerprint

Genotype
Interferons
Ribavirin
Therapeutics
Chronic Hepatitis C
Standard of Care
Hepacivirus
Sample Size
Antiviral Agents
Nucleotides

Keywords

  • Boceprevir
  • Direct-acting antivirals
  • Hepatitis C
  • IL28B polymorphism
  • Interferon
  • Ribavirin
  • Short duration treatment
  • Telaprevir

ASJC Scopus subject areas

  • Hepatology

Cite this

What's new in HCV genotype 2 treatment. / Mangia, Alessandra; Mottola, Leonardo.

In: Liver International, Vol. 32, No. SUPPL. 1, 02.2012, p. 135-140.

Research output: Contribution to journalArticle

@article{caeb7d6fbea9435493b04237da2fa688,
title = "What's new in HCV genotype 2 treatment",
abstract = "Genotype 2 (HCV-2) accounts for 8{\%} of the patients with chronic hepatitis C virus in Europe. Because of the favourable response to interferon (IFN)-based treatment, this group is considered an 'easy-to-treat' genotype along with HCV-3. However, experimental and clinical data suggest possible differences between HCV-2 and -3. Recently, subtle differences in treatment efficacy have also been shown in response-guided treatment studies. In these studies, the duration of pegylated interferon (PEG-IFN) and ribavirin (RBV) treatment was tailored according to treatment response. Although SVR rates were similar between HCV-2 and HCV-3 patients after a rapid virological response (RVR), in the absence of RVR, the rates were lower in HCV-3 than in HCV-2. The triple combination treatment, including direct-acting antivirals (DAA) that will be commercialized in the coming months might increase SVR rates in this particular subgroup of patients. According to existing results, telaprevir might be beneficial in HCV-2 but not in HCV-3 patients. A nucleotide analogue polymerase inhibitor, PSI-7977 by Pharmasett has been shown to be active against both. The role of the IL28B polymorphism as a predictor of response to the current standard of care (SoC), PEG-IFN and RBV treatment is the subject of debate, but this mainly seems to be because of the small size of the samples in the studies performed so far. Existing results suggest that the genetic evaluation of IL28B may be useful in patients with HCV-2 for predicting response in patients without RVR.",
keywords = "Boceprevir, Direct-acting antivirals, Hepatitis C, IL28B polymorphism, Interferon, Ribavirin, Short duration treatment, Telaprevir",
author = "Alessandra Mangia and Leonardo Mottola",
year = "2012",
month = "2",
doi = "10.1111/j.1478-3231.2011.02710.x",
language = "English",
volume = "32",
pages = "135--140",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - What's new in HCV genotype 2 treatment

AU - Mangia, Alessandra

AU - Mottola, Leonardo

PY - 2012/2

Y1 - 2012/2

N2 - Genotype 2 (HCV-2) accounts for 8% of the patients with chronic hepatitis C virus in Europe. Because of the favourable response to interferon (IFN)-based treatment, this group is considered an 'easy-to-treat' genotype along with HCV-3. However, experimental and clinical data suggest possible differences between HCV-2 and -3. Recently, subtle differences in treatment efficacy have also been shown in response-guided treatment studies. In these studies, the duration of pegylated interferon (PEG-IFN) and ribavirin (RBV) treatment was tailored according to treatment response. Although SVR rates were similar between HCV-2 and HCV-3 patients after a rapid virological response (RVR), in the absence of RVR, the rates were lower in HCV-3 than in HCV-2. The triple combination treatment, including direct-acting antivirals (DAA) that will be commercialized in the coming months might increase SVR rates in this particular subgroup of patients. According to existing results, telaprevir might be beneficial in HCV-2 but not in HCV-3 patients. A nucleotide analogue polymerase inhibitor, PSI-7977 by Pharmasett has been shown to be active against both. The role of the IL28B polymorphism as a predictor of response to the current standard of care (SoC), PEG-IFN and RBV treatment is the subject of debate, but this mainly seems to be because of the small size of the samples in the studies performed so far. Existing results suggest that the genetic evaluation of IL28B may be useful in patients with HCV-2 for predicting response in patients without RVR.

AB - Genotype 2 (HCV-2) accounts for 8% of the patients with chronic hepatitis C virus in Europe. Because of the favourable response to interferon (IFN)-based treatment, this group is considered an 'easy-to-treat' genotype along with HCV-3. However, experimental and clinical data suggest possible differences between HCV-2 and -3. Recently, subtle differences in treatment efficacy have also been shown in response-guided treatment studies. In these studies, the duration of pegylated interferon (PEG-IFN) and ribavirin (RBV) treatment was tailored according to treatment response. Although SVR rates were similar between HCV-2 and HCV-3 patients after a rapid virological response (RVR), in the absence of RVR, the rates were lower in HCV-3 than in HCV-2. The triple combination treatment, including direct-acting antivirals (DAA) that will be commercialized in the coming months might increase SVR rates in this particular subgroup of patients. According to existing results, telaprevir might be beneficial in HCV-2 but not in HCV-3 patients. A nucleotide analogue polymerase inhibitor, PSI-7977 by Pharmasett has been shown to be active against both. The role of the IL28B polymorphism as a predictor of response to the current standard of care (SoC), PEG-IFN and RBV treatment is the subject of debate, but this mainly seems to be because of the small size of the samples in the studies performed so far. Existing results suggest that the genetic evaluation of IL28B may be useful in patients with HCV-2 for predicting response in patients without RVR.

KW - Boceprevir

KW - Direct-acting antivirals

KW - Hepatitis C

KW - IL28B polymorphism

KW - Interferon

KW - Ribavirin

KW - Short duration treatment

KW - Telaprevir

UR - http://www.scopus.com/inward/record.url?scp=84855242247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855242247&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2011.02710.x

DO - 10.1111/j.1478-3231.2011.02710.x

M3 - Article

VL - 32

SP - 135

EP - 140

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - SUPPL. 1

ER -